Ministers are under pressure to outline their approach to Chinese companies operating within the UK’s burgeoning genomics sector. The potential risk of foreign exploitation has fueled calls for stringent measures akin to those taken by the US and Europe.
Senior Conservative figures have questioned whether Labour will match international steps aimed at protecting vital health data.
Genomics, the field focusing on the study of human genetic material, holds transformative potential for personalized healthcare solutions. However, the accessibility of such sensitive information raises significant security worries.
The focus on safeguarding genomic data follows broader concerns about Chinese involvement in emerging technologies. In 2020, the UK banned Huawei, a Shenzhen-based telecom giant, from its 5G network due to security fears. Similar issues have since emerged concerning ByteDance’s social media app, TikTok, which has links to Beijing.
In a letter addressed to Cabinet Office minister Abena Oppong-Asare, John Glen, the shadow cabinet office minister, warned of Chinese genomics firms’ alleged ties to state-driven data collection.
Glen asserted that Beijing seeks to “harvest as much DNA data as possible globally and dominate the genomics industry supply chain.”
Glen highlighted that under Chinese law, private entities must share data with government authorities. He pointed out that both the US and Europe have enacted measures to limit Chinese influence, including restrictions on government contracts involving foreign biotech firms.
He called on Labour to commit to protective strategies, either through a new Biological Security Strategy or through targeted debarments.
“In light of the Prime Minister’s desire to pursue closer economic relations with China, many will want reassurances that they are committed to protecting the critical genomics data industry from the security and privacy risks posed by overexposure to foreign companies. It is vital that this data, which has significant implications for future UK healthcare strategies, cannot be leveraged by other states.”
John Glen
Government’s Response and Industry Reassurances
Cabinet Office minister Abena Oppong-Asare confirmed that any decision to exclude foreign companies under the Procurement Act would be handled “on a case-by-case basis.”
She explained that debarment would follow a “rigorous investigation process,” with outcomes published on an official debarment list, detailing the reasons behind such decisions.
“Ministers are actively engaging with UK data repositories to ensure that their protocols reflect up-to-date risk assessments and patients’ data is protected,” she added.
The implicated companies, BGI Group, and MGI Tech, have denied any association with the Chinese government. BGI emphasized that it is “not state-owned or state-controlled in any way,” noting that all research and services adhere to local laws and global data protection standards, such as GDPR in Europe.
MGI Tech, similarly, described itself as an “independent publicly listed company,” asserting that while it follows applicable Chinese regulations, Beijing has no involvement in its international projects.
Despite these reassurances, calls for more robust measures reflect broader anxieties about safeguarding sensitive health data in an interconnected, digitally reliant world.
A Sensitive Balance
This issue highlights the challenge of balancing international partnerships with national security. With the UK standing as a global leader in genomics, the stakes are particularly high.
Policymakers must tread carefully to preserve advancements in healthcare innovation while ensuring that national interests are not compromised by foreign influence.
Critics argue that any ambiguity in the government’s stance could leave vulnerabilities exposed, especially in an era where data has become a new frontier for global power dynamics.
As such, whether Labour’s approach will be sufficient to quell these concerns remains to be seen, but the call for clarity and action grows louder.
READ ALSO: T-bill Undersubscribed After Six Weeks: Trouble or Temporary Blip? Analyst Weighs In
